Novo VP Weighs In on Approval of Lilly’s Obesity Pill
Jamey Millar, executive vice president, US operations of Novo Nordisk, reacts to Eli Lilly’s once-daily weight-loss pill, called Foundayo, winning FDA approval on "Bloomberg The Close." (Source: Bloomberg)
Original Source
Read the full article at Bloomberg →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.